Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Bullboard Posts
Post by wanttoretireearlyon Mar 20, 2020 9:55am
205 Views
Post# 30830004

What do you think, coincidence?

What do you think, coincidence?March 5, 2020 - a report titled "Global Coronavirus COVID 19 Clinical Trals Insight 2020" comes available. 

The report states "On an average, more than 30 clinical trials are getting conducted at the global level, with hundreds of patients enrolled in it. Out of the 30 clinical trials that have been initiated for finding the treatment, only few have cleared the early stages of trial and are on the urge to begin with the Phase III of their clinical trial."

March 10, 2020 - VXL released news "Vaxil has applied for a US patent (U.S 62/987,310) on a coronavirus vaccine that is intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing an infectious disease as well as methods for producing a peptide vaccine against coronaviruses."

Could VXL be one of the few that got into phase III? Looks like it.

1. Global Coronavirus COVID 19 Clinical Trial Overview
1.1 By Phase
1.2 By Company
1.3 By Country
1.4 By Drug Class

2. Research Phase - COVID 2019 Infections Clinical Pipeline
2.1 Cannabidiol Enriched Extract
2.2 Coronavirus Vaccine - Vaxil BioTherapeutics
2.3 ACE2
2.4 Small Molecule Based Therapeutics
2.5 SARS-CoV-2 Vaccine Therapeutics
2.6 Coronavirus Antibodies
2.7 Recombinant Vaccines
2.8 Recombinant Subunit Vaccine
2.9 Interferon Alpha Therapy
2.10 AdVac® and PER.C6® Based Coronavirus Vaccine
2.11 SARS-CoV-2 Vaccine – Codagenix
2.12 Coronavirus Vaccine - CureVac
2.13 Coronavirus Hybrid Vaccines
2.14 Nanoviricide® Technology
2.15 DNA Coronavirus Vaccine
2.16 FastPharming System™  Based Viral
2.17 Coronavirus Neutralising Antibodies
2.18 Anti-Infective Antibody Therapeutics
2.19 Angiopoietin-Tie2 Signaling Targetting
2.20 Small interfering RNA Based Therapeutics
2.21 INO 4800
2.22 Modified Vaccinia Ankara-Virus-Like Particles  Coronavirus Vaccine
2.23 Neutralising Antibody Therapeutics
2.24 mRNA 1273

3. Preclinical Phase - COVID 2019 Infections Clinical Pipeline
3.1 Rintatolimod
3.2 Matrix-M™ Saponin-Based Adjuvant
3.3 Inactivated Coronavirus Virus Vaccine
3.4 Linear DNA Based Vaccine

4. Clinical Phase - COVID 2019 Infections Clinical Pipeline
4.1 ITMN-191

5. Phase-II - COVID 2019 Infections Clinical Pipeline
5.1 ASC 09F

6. Phase-III - COVID 2019 Infections Clinical Pipeline
6.1 GS 5734

7. Competitve Landscape
7.1 AIM ImmunoTech
7.2 Ascletis
7.3 Gilead Sciences
7.4 iBio Inc
7.5 Inovio Pharmaceuticals
7.6 LineaRx
7.7 Mannin Research
7.8 Moderna Therapeutics
7.9 NanoViricides
7.10 Novavax
7.11 Q BioMed
7.12 Sanofi Pasteur
7.13 Sirnaomics
7.14 Takis
7.15 WuXi Biologics

List of Figures
Figure 1-1: Global - Coronavirus  COVID 19 Clinical Trials By Phase (Number), 2020
Figure 1-2: Global - Coronavirus  COVID 19 Clinical Trials By Phase (%), 2020
Figure 1-3: Global - Coronavirus  COVID 19 Clinical Trials By Drug Class (Number), 2020
Figure 1-4: Global - Coronavirus  COVID 19 Clinical Trials By Country (Number), 2020
Figure 1-5: Global - Coronavirus  COVID 19 Clinical Trials By Drug Class (Number), 2020
https://www.researchandmarkets.com/reports/4997174/global-coronavirus-covid-19-clinical-trials?utm_source=dynamic&utm_medium=CI&utm_code=8t769r&utm_campaign=1361344+-+2020+Coronavirus+(COVID+19)+Clinical+Trials+Insights+by+Phase%2c+Drug+Class+and+Country+-+More+than+30+Drugs+are+in+Clinical+Trials&utm_exec=joca220cid

Bullboard Posts